日本CDMO（合約藥物開發和製造組織）市場規模、佔有率、趨勢分析報告：按產品類型、工作流程、應用、國家、細分市場預測，2024-2030年

Japan Contract Development Manufacturing Organization Market Size, Share & Trends Analysis Report By Product Type, By Workflow, By Application, By Country, And Segment Forecasts, 2024 - 2030

出版日期: 2024年05月08日 | 出版商:

Grand View Research | 英文 127 Pages | 商品交期: 2-10個工作天內

價格

簡介目錄圖表

日本CDMO市場成長及趨勢：

Grand View Research, Inc.最新報告顯示，預計到2030年日本CDMO市場規模將達到194.9億美元，2024年至2030年複合年成長率為6.8%。

生物製藥需求的增加、疾病負擔的增加以及老年人口的增加是一些關鍵的成長要素。各種合約藥物開發和受託製造廠商（CDMO）對設施和服務擴展的投資不斷增加，可能會在預測期內提振市場。

此外，製藥公司增加研發投資正在推動市場成長。隨著製藥公司增加研發投資，他們可能會尋求外部專業知識和資源來加速藥物開發進程。 CDMO 為藥物開發、製造和測試提供專業服務，使其成為尋求委託其研發活動某些方面的製藥公司的寶貴合作夥伴。多家公司正在投資藥品研發活動。例如，2022年3月，藥明康德宣布推出四環黴素相容的自惰性腺病毒（TESSA）技術，以加速用於細胞和基因治療藥物的腺結合病毒的生產。

製藥公司外包服務的增加對日本市場產生了重大影響。隨著公司看到成功的藥物開發和商業化所必需的付加能力的價值，製藥領域外包活動的趨勢正在增加。除了提供專業知識和改善現金流管理之外，外包還提供顯著的製造優勢，例如降低投資風險。

值得注意的是，日本監管機構正在加速再生醫學和基因治療產品的核准。例如，《藥品和醫療設備法案》（PMD法案）、《21世紀治癒法案》和PRIME（優先藥物）計劃的通過幫助日本改善了再生醫學的可及性。監管機構的此類舉措預計將改善該國再生醫學開發和製造的需求。

日本 CDMO 市場報告亮點

原料藥(API) 領域在 2023 年佔據市場主導地位，佔有率為 81.2%。該行業的成長是由競爭性藥物開發和端到端合約開發和受託製造廠商(CDMO) 服務不斷成長的需求所推動的。此外，原料藥製造的進步、生物製藥領域的成長以及老年人口的增加也是支持該領域成長的關鍵因素。
這是由於對生物相似藥、學名藥和再生療法等藥品的強勁需求。商務用CDMO 可以透過提供知識、節省時間和提高成本效益來幫助解決這些情況。
從應用來看，腫瘤領域在2023年將佔據35.3%的銷售佔有率，在檢測類型市場中佔據主導地位。再生醫學產品和用於癌症治療的病毒療法的核准將進一步推動市場成長，而全球癌症患者數量的增加將進一步推動這一領域的發展。此外，藥品研發投資的增加、專利到期以及對癌症治療和生物創新的需求是推動腫瘤學領域成長的因素。

主要市場參與企業的最新趨勢和影響分析
公司/競爭對手分類
供應商情況
市場參與企業分類
- 主要經銷商及通路夥伴名單
- 主要客戶
- 2023年主要企業市場佔有率分析
- Lonza
- Thermo Fisher Scientific, Inc.
- Recipharm AB
- Laboratory Corporation of America Holdings (LabCorp)
- Catalent, Inc.
- WuXi AppTec, Inc.
- Samsung Biologics
- CordenPharma International
- Cambrex Corporation
- Bushu Pharmaceuticals Ltd.
- CMIC HOLDINGS Co., LTD.
- Nipro Corporation
- Sumitomo Chemical Company, Limited

簡介目錄圖表

Product Code: GVR-4-68039-985-5

Japan CDMO Market Growth & Trends:

The Japan CDMO market is expected to reach USD 19.49 billion by 2030 and is projected to register a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The increasing demand for biopharmaceuticals, a high burden of diseases, and the rising geriatric population are some of the key growth drivers. Growing investments by various Contract Development and Manufacturing Organizations (CDMOs) for facility and service expansion are likely to boost the market over the forecast period.

In addition, increasing pharmaceutical R&D investments are driving the market growth. As pharmaceutical companies invest more in R&D, they may seek external expertise and resources to accelerate drug development processes. CDMOs provide specialized services in drug development, manufacturing, and testing, making them valuable partners for pharmaceutical companies looking to outsource certain aspects of their R&D activities. Several players are investing in the R&D activities of pharmaceuticals. For instance, in March 2022, WuXi AppTec launched Tetracycline-Enabled Self-Silencing Adenovirus (TESSA) technology to accelerate the production of adeno-associated viruses for drugs in cell and gene therapy.

The increase in outsourcing services by pharmaceutical companies in the pharmaceutical industry has profoundly impacted the Japan market.The trend of outsourcing activities in the pharmaceutical domain is rising as companies find value in acquiring additional competencies essential for successful drug development & commercialization. Besides providing extended expertise & assisting in improved cash flow management, outsourcing brings significant manufacturing advantages, including reducing investment risks.

Notably, regulatory authorities in Japan have accelerated approval for regenerative medical and gene therapy products. For instance, the adoption of the Pharmaceuticals and Medical Devices Act (PMD Act), 21st Century Cures Act, and PRIME (Priority Medicines) Initiative has helped the country improve access to regenerative medicines. Such initiatives by regulatory agencies are expected to improve the demand for the development and manufacturing of regenerative medicines in the country.

Japan CDMO Market Report Highlights:

The active pharmaceutical ingredient (API) segment dominated the market with a share of 81.2% in 2023. The segment growth is driven by competitive drug development and growing demand for end-to-end Contract Development & Manufacturing Organization (CDMO) services. In addition, advancements in API manufacturing, growth of the biopharmaceutical sector, and the increasing geriatric population are some of the key factors propelling segment growth
Based on workflow, the commercial segment held the largest market share in 2023, attributed to robust demand for pharmaceutical products, such as biosimilar medications, generic medications, and regenerative therapies. This is where commercial CDMOs may help by providing knowledge, saving time, and being cost-effective.
Based on application, the oncology segment dominated the test type market in 2023 with a revenue share of 35.3%, owing to the high cancer burden in the country. Approval of regenerative products and virotherapy for cancer treatment can further support market growth and the segment is further driven by increasing number of cancer cases globally. In addition, increasing pharmaceutical R&D investments, patent expirations, and demand for oncology drugs & biologic innovations are the factors driving the oncology segment growth

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Product Type
- 1.2.2. Work Flow Type
- 1.2.3. Application
- 1.2.4. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
- 1.4.1. Purchased database
- 1.4.2. GVR's internal database
- 1.4.3. Secondary sources
- 1.4.4. Primary research
- 1.4.5. Details of primary research
1.5. Information or Data Analysis
- 1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
- 1.7.1. Commodity flow analysis (Model 1)
- 1.7.2. Approach 1: Commodity flow approach
- 1.7.3. Volume price analysis (Model 2)
- 1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Outlook
2.2. Segment Outlook
- 2.2.1. Product Type
- 2.2.2. Work Flow Type
- 2.2.3. Application
2.3. Competitive Insights

Chapter 3. Japan CDMO Market Variables, Trends & Scope

3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
  - 3.2.1.1. Growing demand for Biopharmaceutical drugs in Japan
  - 3.2.1.2. High geriatric population and growing disease burden in Japan
  - 3.2.1.3. Low cost associated with Outsourcing Drug Manufacturing and Development services
- 3.2.2. Market Restraint Analysis
  - 3.2.2.1. Limited outsourcing opted by big pharma companies
  - 3.2.2.2. Quality Issues While Outsourcing
3.3. Japan CDMO Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis

Chapter 4. Japan CDMO Market: Product Estimates & Trend Analysis

4.1. Definitions and Scope
- 4.1.1. API
- 4.1.2. Drug Product
4.2. Product Market Share, 2023 & 2030
4.3. Segment Dashboard
4.4. Japan CDMO Market Movement Analysis
4.5. Japan CDMO Market Size & Trend Analysis, by Product, 2018 to 2030 (USD Million)
- 4.5.1. API
  - 4.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.2. Type
  - 4.5.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.2.2. Traditional Active Pharmaceutical Ingredient (Traditional API)
  - 4.5.1.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.2.3. Highly Potent Active Pharmaceutical Ingredient (HP-API)
  - 4.5.1.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.2.4. Antibody Drug Conjugate (ADC)
  - 4.5.1.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.2.5. Others
  - 4.5.1.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.3. Synthesis
  - 4.5.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.3.2. Synthetic
  - 4.5.1.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.3.2.2. Solid
  - 4.5.1.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.3.2.3. Liquid
  - 4.5.1.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.3.3. Biotech
  - 4.5.1.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.4. Drug
  - 4.5.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.4.2. Innovative
  - 4.5.1.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.4.3. Generics
  - 4.5.1.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.5. Manufacturing
  - 4.5.1.5.1. Continuous manufacturing
  - 4.5.1.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.1.5.2. Batch manufacturing
  - 4.5.1.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.5.2. Drug Product
  - 4.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.2.2. Oral solid dose
  - 4.5.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.2.3. Semi-solid dose
  - 4.5.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.2.4. Liquid dose
  - 4.5.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  - 4.5.2.5. Others
  - 4.5.2.5.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Japan CDMO Market: Workflow Estimates & Trend Analysis

5.1. Definitions and Scope
- 5.1.1. Clinical
- 5.1.2. Commercial
5.2. Segment Dashboard
5.3. Japan CDMO Market Movement Analysis
5.4. Japan CDMO Market Size & Trend Analysis, by Workflow, 2018 to 2030 (USD Million)
- 5.4.1. Clinical
  - 5.4.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.4.2. Commercial
  - 5.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Japan CDMO Market: Application Estimates & Trend Analysis

6.1. Definitions and Scope
- 6.1.1. Oncology
  - 6.1.1.1. Small Molecule
  - 6.1.1.2. Biologics
- 6.1.2. Infectious Diseases
- 6.1.3. Neurological Disorders
- 6.1.4. Cardiovascular Diseases
- 6.1.5. Metabolic Disorders
- 6.1.6. Autoimmune Diseases
- 6.1.7. Respiratory Diseases
- 6.1.8. Ophthalmology
- 6.1.9. Gastrointestinal Disorders
- 6.1.10. Hormonal Disorders
- 6.1.11. Hematological Disorders
- 6.1.12. Others
6.2. Segment Dashboard
6.3. Japan CDMO Market Movement Analysis
6.4. Japan CDMO Market Size & Trend Analysis, by Application, 2018 to 2030 (USD Million)
- 6.4.1. Oncology
  - 6.4.1.1. Market Estimates and forecast 2018 to 2030 (USD million)
  - 6.4.1.2. Small Molecule
  - 6.4.1.2.1. Market estimates and forecast 2018 to 2030 (USD million)
  - 6.4.1.3. Biologics
  - 6.4.1.3.1. Market estimates and forecast 2018 to 2030 (USD million)
- 6.4.2. Infectious Diseases
  - 6.4.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.3. Neurological Disorders
  - 6.4.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.4. Cardiovascular Diseases
  - 6.4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.5. Metabolic Disorders
  - 6.4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.6. Autoimmune Diseases
  - 6.4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.7. Respiratory Diseases
  - 6.4.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.8. Ophthalmology
  - 6.4.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.9. Gastrointestinal Disorders
  - 6.4.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.10. Hormonal Disorders
  - 6.4.10.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.11. Hematological Disorders
  - 6.4.11.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.4.12. Others
  - 6.4.12.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Competitive Landscape

7.1. Recent Developments & Impact Analysis, By Key Market Participants
7.2. Company/Competition Categorization
7.3. Vendor Landscape
7.4. Market Participant Categorization
- 7.4.1. List of key distributors and channel partners
- 7.4.2. Key customers
- 7.4.3. Key company market share analysis, 2023
- 7.4.4. Lonza
  - 7.4.4.1. Company overview
  - 7.4.4.2. Financial performance
  - 7.4.4.3. Product benchmarking
  - 7.4.4.4. Strategic initiatives
- 7.4.5. Thermo Fisher Scientific, Inc.
  - 7.4.5.1. Company overview
  - 7.4.5.2. Financial performance
  - 7.4.5.3. Product benchmarking
  - 7.4.5.4. Strategic initiatives
- 7.4.6. Recipharm AB
  - 7.4.6.1. Company overview
  - 7.4.6.2. Financial performance
  - 7.4.6.3. Product benchmarking
  - 7.4.6.4. Strategic initiatives
- 7.4.7. Laboratory Corporation of America Holdings (LabCorp)
  - 7.4.7.1. Company overview
  - 7.4.7.2. Financial performance
  - 7.4.7.3. Product benchmarking
  - 7.4.7.4. Strategic initiatives
- 7.4.8. Catalent, Inc.
  - 7.4.8.1. Company overview
  - 7.4.8.2. Financial performance
  - 7.4.8.3. Product benchmarking
  - 7.4.8.4. Strategic initiatives
- 7.4.9. WuXi AppTec, Inc.
  - 7.4.9.1. Company overview
  - 7.4.9.2. Financial performance
  - 7.4.9.3. Product benchmarking
  - 7.4.9.4. Strategic initiatives
- 7.4.10. Samsung Biologics
  - 7.4.10.1. Company overview
  - 7.4.10.2. Financial performance
  - 7.4.10.3. Product benchmarking
  - 7.4.10.4. Strategic initiatives
- 7.4.11. CordenPharma International
  - 7.4.11.1. Company overview
  - 7.4.11.2. Financial performance
  - 7.4.11.3. Product benchmarking
  - 7.4.11.4. Strategic initiatives
- 7.4.12. Cambrex Corporation
  - 7.4.12.1. Company overview
  - 7.4.12.2. Financial performance
  - 7.4.12.3. Product benchmarking
  - 7.4.12.4. Strategic initiatives
- 7.4.13. Bushu Pharmaceuticals Ltd.
  - 7.4.13.1. Company overview
  - 7.4.13.2. Financial performance
  - 7.4.13.3. Product benchmarking
  - 7.4.13.4. Strategic initiatives
- 7.4.14. CMIC HOLDINGS Co., LTD.
  - 7.4.14.1. Company overview
  - 7.4.14.2. Financial performance
  - 7.4.14.3. Product benchmarking
  - 7.4.14.4. Strategic initiatives
- 7.4.15. Nipro Corporation
  - 7.4.15.1. Company overview
  - 7.4.15.2. Financial performance
  - 7.4.15.3. Product benchmarking
  - 7.4.15.4. Strategic initiatives
- 7.4.16. Sumitomo Chemical Company, Limited
  - 7.4.16.1. Company overview
  - 7.4.16.2. Financial performance
  - 7.4.16.3. Product benchmarking
  - 7.4.16.4. Strategic initiatives